Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 2017, Department of Homeland Security Appropriations Act, 2012: Provisions relating to Customs and Border Protection
H.R. 2112, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2012: FDA related provisions
H.R. 2055, Consolidated Appropriations Act, 2012: Provisions relating to health and trade
H.R. 2608, Continuing Appropriations Act, 2012: FDA funding and related provisions
H.R. 3671, Consolidated Appropriations Act, 2012: Provisions relating to health and trade
S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012: HHS related provisions
H.J. RES. 79, Continuing Appropriations Resolutions, 2012

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provision related to authorized generics
H.R. 2182, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives
H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting
H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting
H.R. 3497, MODDERN Cures Act of 2011: Provisions related to data protection
S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements
S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics
S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting
S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives
S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting
International intellectual property issues
Biopharmaceutical innovation policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 1483, Drug Safety Enhancement Act of 2011: Provisions related to supply chain issues
H.R. 2245, Preserving Access to Life-Saving Medications Act of 2011: Provisions related to prescription drug shortages
S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages
S. 1584, Drug Safety and Accountability Act of 2011: Provisions related to supply chain issues
S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B
S. 2672, Preserving Access to Orphan Drugs Act of 2011: Provisions related to orphan drug definition and health reform fee
Best Pharmaceuticals for Children Act (BPCA) reauthorization
Pediatric Research Equity Act (PREA) reauthorization
Health care reform implementation issues
General HHS and FDA related advocacy
Prescription Drug User Fee Act (PDUFA) reauthorization
Anti-counterfeiting and supply chain issues
Biopharmaceutical innovation policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB)
H.R. 675 Strengthening Medicare Anti-Fraud Measures Act of 2010: Provisions related to exclusion issues
H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues
H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues
H.R. 2248 Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D non-interference issues
H.R. 3765, Temporary Payroll Tax Cut Continuation Act of 2011: Provisions related to Medicare
S. 31, Prescription Drug and Health Improvement Act of 2011: Provisions related to Part D non-interference provisions
S. 44, Medicare Prescription Drug Price Negotiation Act of 2011: Provisions related to Part D issues
S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid
S. 560, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues
S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB)
S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues
S. 1251, Medicare and Medicaid FAST Act: Provisions related to Part D issues.
S. 1699, Prescription Drug Cost Reduction Act: Provisions related to Medicare Part B and drug rebates
Advocacy on Medicare/Medicaid issues being considered by the Joint Select Committee on Deficit Reduction

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Korea Free Trade Agreement: Provisions related to intellectual property, market access and public health
Trans-Pacific Strategic Economic Partnership Agreement (TPP): Provisions related to intellectual property, market access and public health issues
Russia Permanent Normal Trade Relations (PNTR)
Turkey Market Access Issues
Issues related to Special 301 and National Trade Estimate (NTE) submissions
Preference Programs
International market access and intellectual property issues
Biopharmaceutical innovation policy issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), State - Dept of (DOS), Natl Security Council (NSC), U.S. Trade Representative (USTR), White House Office, Executive Office of the President (EOP), Treasury - Dept of

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: http://www.phrma.org/about/member-companies

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization